Portfolio
Endpoint Health
“Endpoint Health’s novel platform approach enables precision immunology through the development & delivery of hyper-targeted therapeutics.
Endpoint Health combines therapeutics, therapy guiding tests (companion diagnostics), & artificial intelligence to develop a platform for hyper-targeted therapies to treat immune-driven chronic & critical care conditions such as: Acute Respiratory Distress Syndrome (ARDS), Sepsis, Rheumatoid Arthritis (RA), Inflammatory Bowel Syndrome (IBD), amongst others.
Clinical partnerships with over 60 hospitals (Including: Cleveland Clinical, Vanderbilt, amongst others), power the data that drive their proprietary platform to identify unique biological signals. These biomarkers enable the development of precision companion diagnostics to identify / stratify high responder patient groups & inform the in-licensing of therapeutic assets to follow new clinical path(s) (similar to drug repurposing, in this case, the therapy is used for its original purpose, but it’s developed for a new disease).
This allows Endpoint Health to rapidly progress known assets with a proven safety profile into the clinic with patient subpopulations that they have identified as high responders therefore dramatically increasing drug efficacy / performance, thus creating a platform approach to repeatedly / reliably advance low risk assets with blockbuster potential into the clinic, & elevate the current standard of care.”
Founders: Jason Springs, Diego Rey, & Leonardo Teixeira
Location: San Francisco, California
Category: Life Sciences / Therapeutics / Precision Medicine
Company Stage: Series A
Co-Investors: Mayfield Fund, AME Cloud Ventures, Wireframe Ventures, amongst others
Team
What Founders Say…
“Getting Alix Ventures involved felt like a jolt of lightning! They served as a key reference to help us secure our oversubscribed $52M Series A round & have only upped their support since - providing countless intros to follow on VCs, Pharma KOLs, industry experts, & more! They’ve also provided us numerous opportunities for thought leadership with their BIOS Platform, landed us a speaking slot at SynBio Beta’s Built with Biology Conference, & made sure our Series A announcement reached all 4 corners of the Life Sciences universe. They truly get the founder mentality & the “this needs to be done yesterday” attitude. Grateful for their support!”
- Jason Springs, Co-Founder & CEO @ Endpoint Health
